The Build-vs-Buy Debate Is the Wrong One for Regulatory-Grade AI

Short summary

Yseop argues the build-versus-buy framework is fundamentally misaligned for regulatory-grade AI in pharmaceutical companies. Rather than choosing one path, mature pharma organizations are implementing hybrid strategies combining custom-built AI with vendor solutions. Success requires knowing which components demand custom development versus outsourcing.

• •Build-vs-buy is a false binary for regulated industries
• •Pharma leaders are adopting hybrid approaches combining custom and vendor solutions
• •Strategic layering balances regulatory control with operational efficiency

Generated with AI, which can make mistakes.